• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Two FDA Approvals Will Impact Ultragenyx Stock (RARE)

    Simply Wall St·11/05/2026 04:58:53
    Listen to the news
    • Ultragenyx Pharmaceutical reported Q3 2026 revenue of US$173 million and a quarterly net loss of US$118 million, while securing FDA approval for two gene therapies, GENGLYCOS and FAYUVI, and outlining significant cost reductions tied to a 20% workforce cut.
    • The business is effectively swapping breadth for focus by discontinuing certain late stage programs, trimming expenses, and leaning on new gene therapy launches plus US$413 million of Priority Review Voucher proceeds to support its reaffirmed path toward GAAP profitability in 2027.
    • We will examine how Ultragenyx Pharmaceutical's profitability narrative aligns with its new gene therapy approvals and expense reduction plan.

    See how Ultragenyx Pharmaceutical compares to other rare-disease and high-research-cost plays by focusing on our hand-picked 31 resilient stocks with low risk scores, which emphasize resilience even when earnings are still in the red.

    Ultragenyx Pharmaceutical Investment Narrative Recap

    To own Ultragenyx Pharmaceutical, you need to believe the rare disease portfolio and new gene therapies can eventually offset ongoing losses and heavy research spend. The Q3 2026 update shows revenue of US$173 million and a quarterly net loss of US$118 million. Management is leaning on cost cuts, PRV proceeds and a narrower pipeline to support its plan for 2027 GAAP profitability.

    The near term swing factor is execution on gene therapy launches and expense reductions actually flowing through to the income statement. The main operational risk is that cash burn and negative equity persist if uptake for GENGLYCOS and FAYUVI or cost savings do not match the reaffirmed guidance.

    The reaffirmed outlook for 2026 and 2027 is the announcement that matters most here. Ultragenyx Pharmaceutical kept 2026 revenue guidance at US$730 million to US$760 million, excluding new product launches, and reiterated its aim for full year GAAP profitability in 2027 and beyond. That sits alongside Q3 revenue of US$173 million and a loss per share of US$1.16.

    For you, that guidance sets a clear execution yardstick. Progress from here rests on converting recent approvals into meaningful therapy sales, keeping R&D and SG&A in line with the 20% workforce reduction, and managing cash after the US$413 million Priority Review Voucher proceeds. Any slippage against those pieces would pressure the profitability plan.

    Ultragenyx Pharmaceutical's current analyst narrative points to revenue of US$1.3b and earnings of US$63.2 million by 2029, built on an assumed 20.6% yearly revenue growth rate and an earnings swing of roughly US$649 million from a loss of US$586.0 million today to forecast consensus earnings of US$63.2 million.

    Uncover how Ultragenyx Pharmaceutical's fair value indicates a 53% potential upside to its current price before sentiment narrows that difference.

    NasdaqGS:RARE 1-Year Stock Price Chart
    NasdaqGS:RARE 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts focus on Ultragenyx Pharmaceutical’s revenue potential from gene therapies. Before this week’s Q3 2026 results and approvals, the bullish camp was modelling about US$1.9b of revenue and US$334.0 million of earnings by 2029. Your view on whether this new information shifts those projections is what really matters.

    Explore 4 other Ultragenyx Pharmaceutical fair value estimates, including one that suggests up to 995% upside from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Ultragenyx Pharmaceutical?

    If Ultragenyx Pharmaceutical has put rare diseases and cash burn on your radar, it can help to widen the lens and compare it with other businesses that fit clear financial themes using the Simply Wall St Screener.

    • For investors who care most about capital preservation and smoother ride quality, focus on companies flagged as 31 resilient stocks with low risk scores that prioritise balance sheet strength and lower overall risk profiles.
    • If value is your anchor, use the screener highlighting 34 high quality undervalued stocks to spot businesses where fundamentals and price appear out of sync.
    • For those who want potential income on top of price returns, the tool that surfaces 5 dividend fortresses can help you narrow in on higher yielding payers with an emphasis on durability.